Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi-Ran Xu

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Annals of Neurology|March 17, 2026
Novel Monoclonal Antibody Detects Small Aβ Oligomers More Sensitively Than Lecanemab in Alzheimer's Disease CSF, Serum and Culture MediaYi Ran Xu, Youqi Tao, Alexandra M Lish, et al.
Alzheimer'S Research & Therapy|July 11, 2025
An improved immunoassay detects Aβ oligomers in human biofluids: their CSF levels rise with tau and phosphotau levelsTing Yang, Yi Ran Xu, Shanxue Jin, et al.
Cell Reports|June 30, 2026
Immunotherapy with B28, an antibody to Aβ oligomers, potently decreases amyloid plaques, microgliosis, and memory decline in APP knock-in miceTing Yang, Yi Ran Xu, Shaomin Li, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 14, 2026
Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer's disease brainKatrine D Bjørnholm, P Monroe Butler, Anna E Francis, et al.
The Lancet. Neurology|January 24, 2026
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1<sup>Glu280Ala</sup> mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trialPierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Annals of Neurology|March 17, 2026
Novel Monoclonal Antibody Detects Small Aβ Oligomers More Sensitively Than Lecanemab in Alzheimer's Disease CSF, Serum and Culture MediaYi Ran Xu, Youqi Tao, Alexandra M Lish, et al.
Alzheimer'S Research & Therapy|July 11, 2025
An improved immunoassay detects Aβ oligomers in human biofluids: their CSF levels rise with tau and phosphotau levelsTing Yang, Yi Ran Xu, Shanxue Jin, et al.
Cell Reports|June 30, 2026
Immunotherapy with B28, an antibody to Aβ oligomers, potently decreases amyloid plaques, microgliosis, and memory decline in APP knock-in miceTing Yang, Yi Ran Xu, Shaomin Li, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 14, 2026
Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer's disease brainKatrine D Bjørnholm, P Monroe Butler, Anna E Francis, et al.
The Lancet. Neurology|January 24, 2026
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1<sup>Glu280Ala</sup> mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trialPierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, et al.
Pageof 2